As of January 24, 2025, Embecta (EMBC) has a market cap of $1.09 billion USD. According to our data, Embecta is ranked No.5089 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 24, 2025 | $1.09 B |
-9.25%
|
Dec 31, 2024 | $1.20 B |
13.56%
|
Dec 29, 2023 | $1.06 B |
-23.11%
|
Dec 30, 2022 | $1.37 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Medtronic
MDT
|
$114.44 B |
-0.000 M
|
Ireland
|
Abbott Laboratories
ABT
|
$213.72 B |
0.003 M
|
USA
|
DexCom
DXCM
|
$34.26 B |
0.001 M
|
USA
|
Insulet
PODD
|
$19.44 B |
0.001 M
|
USA
|
Novo Nordisk
NVO
|
$358.02 B |
85.091 B
|
Denmark
|
Eli Lilly
LLY
|
$689.42 B |
-0.013 M
|
USA
|
Johnson & Johnson
JNJ
|
$353.05 B |
-0.000 M
|
USA
|
Stryker Corporation
SYK
|
$150.01 B |
0.000 M
|
USA
|
Becton Dickinson
BDX
|
$69.74 B |
0.002 M
|
USA
|
Tandem Diabetes Care
TNDM
|
$2.30 B |
0.000 M
|
USA
|
Edwards Lifesciences
EW
|
$40.65 B |
-0.001 M
|
USA
|
Boston Scientific
BSX
|
$149.80 B |
-0.007 M
|
USA
|
Zimmer Biomet
ZBH
|
$22.10 B |
0.001 M
|
USA
|
Market Cap | = | EMBC Stock Price | * | EMBC Shares Outstanding |
= | $18.74 | * | 58.13 M | |
= | $1.09 B |